Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quemliclustat + zimberelimab
- Development stage
- Phase 2
- Lead developer
- Arcus Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Quemliclustat + zimberelimab is an investigational combination therapy being studied for the treatment of advanced or metastatic pancreatic cancer. Quemliclustat is a potent and selective small molecule inhibitor of CD73, an ectoenzyme responsible for producing immunosuppressive adenosine in the tumor microenvironment, which can hinder the immune response to cancer. By blocking CD73, quemliclustat aims to reduce adenosine-mediated immunosuppression and enhance anti-tumor immune activity. Zimberelimab is a monoclonal antibody that targets programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor and thereby augmenting T cell-mediated responses against tumors. The combination is under clinical investigation, including in phase I/II and III trials, typically alongside chemotherapy regimens such as gemcitabine and nab-paclitaxel or mFOLFIRINOX. The principal developer for both agents in combination is Arcus Biosciences in collaboration with Gilead Sciences.
- Other names
- quemliclustat + zimberelimab
02
Targets
NT5E (Cluster of Differentiation 73)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on quemliclustat + zimberelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quemliclustat + zimberelimab.